SND1 and colorectal carcinoma: Our research demonstrated that SPT6 synergized with staphylococcal nuclease and Tudor domain containing 1 (SND1) to promote CRC progression by targeting human telomerase reverse transcriptase (hTERT) and put forward that inhibiting SPT6‐SND1‐hTERT axis may create a therapeutic vulnerability in CRC.